<?xml version="1.0" encoding="UTF-8"?>
<p class="p">To counterpart these limitations, herein it was observed that the remarkable antibacterial activity was present at very low concentration and, when combined with commonly therapeutically used antimicrobials, even at sub-inhibitory concentrations, thus making it reasonable to have further investigations on the best TTO percentage to be used for clinical purpose. On the other hand, a recent study performed in an animal model of bacterial and fungal pneumonia showed the efficacy of inhalable TTO nanoemulsion as a promising and intriguing local therapy to overcome difficulties in TTO formulation [
 <xref rid="B37-molecules-23-02584" ref-type="bibr" class="xref">37</xref>].
</p>
